Vanguard Capital Management
ALDX icon

Vanguard Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Vanguard Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.03M Sell
2,361,796
-1,946
-0.1% -$3.35K ﹤0.01% 3119
2026
Q1 		$3.99M Buy
+2,363,742
New +$10.4M ﹤0.01% 3142

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management's ALDX Position: Q2 2026 in Review

Vanguard Capital Management reduced its Aldeyra Therapeutics (ALDX) stake by 0.08% in Q2 2026, selling an estimated $3.35K and leaving 2,361,796 shares worth $5.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

Vanguard Capital Management first reported a position in ALDX in Q1 2026 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Vanguard Capital Management held 2,361,796 shares of Aldeyra Therapeutics worth $5.03M as of Q2 2026.
  • Vanguard Capital Management sold 1,946 Aldeyra Therapeutics shares in Q2 2026, an estimated $3.35K.
  • Aldeyra Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3119 holding.
  • Vanguard Capital Management first reported a position in Aldeyra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.